Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 12.25 mg (equivalent: lenvatinib, qty 10 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; iron oxide red; calcium carbonate; propylene glycol; hyprolose; mannitol; potassium hydroxide; titanium dioxide; hypromellose; iron oxide black; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 4.9 mg (equivalent: lenvatinib, qty 4 mg) - capsule, hard - excipient ingredients: iron oxide yellow; propylene glycol; potassium hydroxide; mannitol; iron oxide black; titanium dioxide; hypromellose; purified talc; iron oxide red; calcium carbonate; microcrystalline cellulose; hyprolose; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.,differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

United States - English - NLM (National Library of Medicine)

eisai inc. - lenvatinib (unii: ee083865g2) (lenvatinib - unii:ee083865g2) - lenvatinib 10 mg - lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (dtc).  lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc). lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced rcc following one prior anti-angiogenic therapy. lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc). lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (ec) that is mismatch repair proficient (pmmr), as determined by an fda-approved test, or not microsatellite instability-high (msi-h), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see dosage and administration ( 2.1 )] . none. ris

New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - lenvatinib mesilate 12.25mg equivalent to lenvatinib 10mg - capsule - 10 mg - active: lenvatinib mesilate 12.25mg equivalent to lenvatinib 10mg excipient: calcium carbonate hyprolose as 25mg low-substituted hydroxypropyl cellulose + 3mg hydroxypropylcellulose hypromellose iron oxide black iron oxide red iron oxide yellow mannitol microcrystalline cellulose potassium hydroxide propylene glycol purified talc shellac titanium dioxide - lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

eisai new zealand limited - lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg - capsule - 4 mg - active: lenvatinib mesilate 4.9mg equivalent to lenvatinib 4mg excipient: calcium carbonate hyprolose as 25mg low-substituted hydroxypropyl cellulose + 3mg hydroxypropylcellulose hypromellose iron oxide black iron oxide red iron oxide yellow mannitol microcrystalline cellulose potassium hydroxide propylene glycol purified talc shellac titanium dioxide - lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine refractory differentiated thyroid cancer.

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 24mg - lenvatinib (lenvatinib mesylate) 24mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 20mg - lenvatinib (lenvatinib mesylate) 20mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 14mg - lenvatinib (lenvatinib mesylate) 14mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 10mg - lenvatinib (lenvatinib mesylate) 10mg - antineoplastic agents

Canada - English - Health Canada

eisai limited - lenvatinib (lenvatinib mesylate) - capsule - 8mg - lenvatinib (lenvatinib mesylate) 8mg - antineoplastic agents